{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T01:42:58Z","timestamp":1649122978089},"reference-count":21,"publisher":"Akademiai Kiado Zrt.","issue":"Supplement 2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Orvosi Hetilap"],"published-print":{"date-parts":[[2014,3]]},"abstract":"Diagnosis and treatment of hepatitis B and D virus infections mean that the patient is able to maintain working capacity, increase quality of life, prevent cancer, and prolong life expectancy, while the society benefits from eliminating the chances of further transmission of the viruses, and decreasing the overall costs of serious complications. The guideline delineates the treatment algorithms for 2014, which is agreed on a consensus meeting of specialists involved in the treatment of the above diseases. The prevalence of hepatitis B virus infection in the Hungarian general population is 0.5\u20130.7%. The indications of treatment is based upon viral examinations (including viral nucleic acid determination), determinations of disease activity and stage (including biochemical, pathologic, and\/or non-invasive methods), and excluding contraindications. To avoid unnecessary side effects and for cost-effective approach the guideline emphasizes the importance of quick and detailed virologic evaluations, the applicability of transient elastography as an acceptable alternative of liver biopsy in this regard, as well as the relevance of appropriate consistent follow up schedule for viral response during therapy. The first choice of therapy in chronic hepatitis B infection can be pegylated interferon for 48 weeks or continuous entecavir or tenofovir therapy. The latter two must be continued for at least 12 months after hepatitis B surface antigen seroconversion. Adefovir dipivoxil is recommended mainly in combination therapy. Lamivudine is no longer a first choice; patients currently taking lamivudine must switch if response is inadequate. Appropriate treatment of patients taking immunosuppressive medications is highly recommended. Pegylated interferon based therapy is recommended for the treatment of concomitant hepatitis D infection. Orv. Hetil., 2014, 155(Szuppl. 2), 25\u201335.<\/jats:p>","DOI":"10.1556\/oh.2013.29894","type":"journal-article","created":{"date-parts":[[2014,3,17]],"date-time":"2014-03-17T01:00:58Z","timestamp":1395018058000},"page":"25-36","source":"Crossref","is-referenced-by-count":1,"title":["Diagnosis and treatment of chronic hepatitis B and D. Hungarian national consensus guideline"],"prefix":"10.1556","volume":"155","author":[{"given":"G\u00e1bor","family":"Horv\u00e1th","sequence":"first","affiliation":[{"name":"Budai Hepatol\u00f3giai Centrum Budapest Egry J\u00f3zsef u. 1\u20133. 1111"},{"name":"Szent J\u00e1nos K\u00f3rh\u00e1z \u00e9s \u00c9szak-budai Egyes\u00edtett K\u00f3rh\u00e1zak Hepatol\u00f3giai Szakambulancia Budapest"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e9la","family":"Hunyady","sequence":"additional","affiliation":[{"name":"Somogy Megyei Kaposi M\u00f3r Oktat\u00f3 K\u00f3rh\u00e1z Belgy\u00f3gy\u00e1szati Oszt\u00e1ly Kaposv\u00e1r"},{"name":"P\u00e9csi Tudom\u00e1nyegyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar I. Belgy\u00f3gy\u00e1szati Klinika P\u00e9cs"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judit","family":"Gervain","sequence":"additional","affiliation":[{"name":"Szent Gy\u00f6rgy Egyetemi Oktat\u00f3 K\u00f3rh\u00e1z I. Belgy\u00f3gy\u00e1szat \u00e9s Molekul\u00e1ris Diagnosztikai Laborat\u00f3rium Sz\u00e9kesfeh\u00e9rv\u00e1r"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"Lengyel","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar II. Belgy\u00f3gy\u00e1szati Klinika Budapest"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mih\u00e1ly","family":"Makara","sequence":"additional","affiliation":[{"name":"Egyes\u00edtett Szent Istv\u00e1n \u00e9s Szent L\u00e1szl\u00f3 K\u00f3rh\u00e1z Budapest"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alajos","family":"P\u00e1r","sequence":"additional","affiliation":[{"name":"P\u00e9csi Tudom\u00e1nyegyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar I. Belgy\u00f3gy\u00e1szati Klinika P\u00e9cs"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferenc","family":"Szalay","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar I. Belgy\u00f3gy\u00e1szati Klinika Budapest"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e1szl\u00f3","family":"Telegdy","sequence":"additional","affiliation":[{"name":"Egyes\u00edtett Szent Istv\u00e1n \u00e9s Szent L\u00e1szl\u00f3 K\u00f3rh\u00e1z Budapest"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Istv\u00e1n","family":"Tornai","sequence":"additional","affiliation":[{"name":"Debreceni Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Orvos- \u00e9s Eg\u00e9szs\u00e9gtudom\u00e1nyi Centrum Belgy\u00f3gy\u00e1szati Int\u00e9zet Debrecen"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"425","reference":[{"key":"1","unstructured":"Management of chronic B and D hepatitis. The guideline of the Hungarian Ministry of Human Resources. [A Nemzeti Er\u0151forr\u00e1s Miniszt\u00e9rium Szakmai Protokollja a B- \u00e9s D-hepatitis kezel\u00e9s\u00e9r\u0151l]. Eg\u00e9szs\u00e9g\u00fcgyi K\u00f6zl\u00f6ny, 2011, 61<\/i>(7), 1379\u20131385. www.kozlonyok.hu\/kozlonyok\/Kozlonyok\/6\/PDF\/2011\/7.pdf<\/a> [Hungarian]"},{"key":"2","unstructured":"Horv\u00e1th, G., Gervain, J., Hunyady, B., et al.:<\/i> Management of chronic hepatitis B and D. Hungarian Guideline [Protokoll a B- \u00e9s D-hepatitis antivir\u00e1lis kezel\u00e9s\u00e9re.] Magyar Belorvosi Archivum, 2012, 65<\/i>(4), 203\u2013213. [Hungarian]"},{"key":"3","doi-asserted-by":"crossref","unstructured":"EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. European Association for the Study of the Liver. J. Hepatol., 2012, 57<\/i>(1), 167\u2013185.","DOI":"10.1016\/j.jhep.2012.02.010"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Lok, A. S., McMahon, B. J.:<\/i> Chronic hepatitis B: update 2009. Hepatology, 2009, 50<\/i>(3), 661\u2013662.","DOI":"10.1002\/hep.23190"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Horv\u00e1th, G.:<\/i> New drugs for the treatment of chronic hepatitis B and interdisciplinary aspects of chronic hepatitis B virus infection. [A hepatitis B-v\u00edrus-fert\u0151z\u00e9s \u00faj gy\u00f3gyszerei \u00e9s interdiszciplin\u00e1ris vonatkoz\u00e1sai.] Orv. Hetil., 2013, 154<\/i>(29), 1142\u20131150 [Hungarian]","DOI":"10.1556\/OH.2013.29625"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Makara, M., Horv\u00e1th, G., Gervain, J., et al.:<\/i> Hungarian consensus guideline for the diagnosis and treatment of B, C, and D viral hepatitis. [Aj\u00e1nl\u00e1s a B-, a C- \u00e9s a D-v\u00edrus hepatitisek diagnosztik\u00e1j\u00e1ra \u00e9s antivir\u00e1lis kezel\u00e9s\u00e9re.] Orv. Hetil., 2012, 153<\/i>(10), 375\u2013394. [Hungarian]","DOI":"10.1556\/OH.2012.29338"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Tornai, I.:<\/i> Interferon-based versus direct antiviral therapy in patients with chronic hepatitis B. [Interferonalap\u00fa versus direkt antivir\u00e1lis ter\u00e1pia a kr\u00f3nikus B hepatitis kezel\u00e9s\u00e9ben.] Orv. Hetil., 2011, 152<\/i>(22), 869\u2013874. [Hungarian]","DOI":"10.1556\/OH.2011.29081"},{"key":"8","unstructured":"P\u00e1r, A., P\u00e1r, G.:<\/i> Non-invasive fibrosis assessment in chronic hepatitis C: aspartate-aminotransferase to platelet ratio index (APRI) and transient elastography (FibroScan). [Nem invaz\u00edv fibrosisdiagnosztika kr\u00f3nikus C-hepatitisben: aszpart\u00e1t-aminotranszfer\u00e1z\/thrombocyta h\u00e1nyadosindex (APRI) \u00e9s tranziens elasztogr\u00e1fia (FibroScan)]. Orv. Hetil., 2010, 151<\/i>(47), 1951\u20131955. [Hungarian]"},{"key":"9","unstructured":"Horv\u00e1th, G.:<\/i> New non-invasive tool for assessment of liver fibrosis: transient elastography. [A m\u00e1jfibrosis meghat\u00e1roz\u00e1s\u00e1nak \u00faj, noninvaz\u00edv m\u00f3dszere: tranziens elasztogr\u00e1fia (FibroScan).] Orv. Hetil., 2011, 152<\/i>(22), 860\u2013865. [Hungarian]"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Chen, C. J., Yang, H. I., Su, J., et al.:<\/i> Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA, 2006, 295<\/i>(1), 65\u201373.","DOI":"10.1001\/jama.295.1.65"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Chen, C. J., Yang, H. I., Su, J., et al.:<\/i> Serial monitoring of viral load and serum alanine aminotransferase level and the risk of hepatocellular carcinoma (HCC): R.E.V.E.A.L.-HBV study update. J. Hepatol., 2008, 48<\/i>(Suppl. 2), S61 (A141).","DOI":"10.1016\/S0168-8278(08)60143-9"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Marcellin, P., Gane, E., Buti, M., et al.:<\/i> Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet, 2013, 381<\/i>(9865), 468\u2013475.","DOI":"10.1016\/S0140-6736(12)61425-1"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Shim, J. H., Lee, H. C., Kim, K. M., et al.:<\/i> Efficacy of entecavir in teratment-na\u00efve patients with hepatitis B virus-related decompensated cirrhosis. J. Hepatol., 2010, 52<\/i>(2), 176\u2013182.","DOI":"10.1016\/j.jhep.2009.11.007"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Bzowej, N. H.:<\/i> Hepatitis B therapy in pregnancy. Curr. Hepat. Rep., 2010, 9<\/i>(4), 197\u2013204.","DOI":"10.1007\/s11901-010-0059-x"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Han, G. R., Cao, M. K., Zhao, W., et al.:<\/i> A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. Br. J. Hepatol., 2011, 55<\/i>(6), 1215\u20131221.","DOI":"10.1016\/j.jhep.2011.02.032"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Raimondo, G., Pollicino, T., Cacciola, I., et al.:<\/i> Occult hepatitis B virus infection. J. Hepatol., 2007, 46<\/i>(1), 160\u2013170.","DOI":"10.1016\/j.jhep.2006.10.007"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Evens, A. M., Jovanovic, B. D., Su, Y. C., et al.:<\/i> Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann. Oncol., 2011, 22<\/i>(5), 1170\u20131180.","DOI":"10.1093\/annonc\/mdq583"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Lalazar, G., Rund, D., Shouval, D.:<\/i> Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br. J. Haematol., 2007, 136<\/i>(5), 699\u2013712.","DOI":"10.1111\/j.1365-2141.2006.06465.x"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Marzano, A., Angelucci, E., Andreone, P., et al.:<\/i> Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig. Liver Dis., 2007, 39<\/i>(5), 397\u2013408.","DOI":"10.1016\/j.dld.2006.12.017"},{"key":"20","unstructured":"Cornberg, M., Protzer, U., Petersen, J., et al.:<\/i> Prophylaxis, diagnosis and therapy of hepatitis B virus infection \u2013 the German guideline. Z. Gastroenterol., 2011, 49<\/i>(7), 871\u2013930."},{"key":"21","doi-asserted-by":"crossref","unstructured":"Vigan\u00f2, M., Vener, C., Lampertico, P., et al.:<\/i> Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT. Bone Marrow Transplant., 2011, 46<\/i>(1), 125\u2013131.","DOI":"10.1038\/bmt.2010.70"}],"container-title":["Orvosi Hetilap"],"original-title":[],"language":"hu","link":[{"URL":"https:\/\/www.akademiai.com\/doi\/pdf\/10.1556\/OH.2013.29894","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T09:54:31Z","timestamp":1590141271000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/doi\/10.1556\/oh.2013.29894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":21,"journal-issue":{"issue":"Supplement 2","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["10.1556\/OH.2013.29894"],"URL":"https:\/\/doi.org\/10.1556\/oh.2013.29894","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}